Editorial Comment
The Promise of Technetium-99m-Based Perfusion Imaging Agents Elias H. Botvinick, MD T he noninvasive scintigraphic assessment of myocardial perfusion has become an important aspect of cardiac evaluation. The method has evolved greatly during the last 15 years, benefiting greatly from technical developments in camera-computer and software design' and by the advent of single photon emission computerized tomographic (SPECT) reconstruction.2 Radionuclide evolution has also contributed to this advance, moving through high energy rubidium-81 to the currently used thallium-201 and the prospective application of technetium 99m-based agents. 3 The method determines relative myocardial perfusion acquired in association with a spectrum of dynamic or pharmacologic "stress" interventions that test coronary flow reserve, often independently of the induction of ischemia. Perfusion scintigraphy is now commonly employed as a diagnostic test in patients with symptoms of unclear origin and as a prognostic test in patients with known coronary disease associated with the spectrum of coronary syndromes. It is also applied to assess the significance of known coronary lesions, to identify the "culprit" lesion, and to guide and evaluate therapy both in symptomatic patients and in those with silent ischemia. Although used less frequently in the evaluation of acute coronary syndromes, there is need for such expanded See p 2152 application to assess regional perfusion, the effects of intervention, and the assessment of viability with acute reperfusion intervention. Economic as well as scientific and clinical considerations will also likely guide study application. As medical costs are brought into greater focus, demands will be made to apply physiologic testing to objectify and justify the need for expensive interventions. When compared with cardiac catheterization and coronary angiography, bypass surgery, and cardiac transplantation, myocardial perfusion scintigraphy falls on the less expensive side of the medical ledger. Further, the pathophysiological results of these radionuclide studies, their noninvasive nature, and their proven relation to prognosis with the added factor of lower cost appear likely to justify more widespread application of this method for economic as well as medical reasons.
Imperfections of the Current Method
Despite past progress, widespread current success, and expanding application, like all methods myocardial perfusion scintigraphy remains imperfect. Much of the deficiency is related to the imperfect nature of the currently employed radiopharmaceutical`01TI.
Although 20`T1 distributes rapidly intracellularly in proportion to relative perfusion, its low 80-keV photon and long, 73-hour physical half-life represent major deficiencies largely responsible, in the former case, for significant attenuation artifacts and, in the latter, for a relatively low limit of injected dose. These problems contribute to the production of a suboptimal image and restrict the imaging protocol. Problematic too is the fact that the radionuclide is cyclotron produced, increasing its cost and reducing its availability, the latter often being critical for application in the acute setting.
Another feature of intracellular`01T1 localization is related to its apparent redistribution. Advantage of this feature is taken when serial imaging is performed to assess normalization of stress-induced defects to determine regional viability of myocardium at ischemic risk. The occurrence of redistribution and the significance of its absence lie at the center of debate regarding assessment of myocardial viability.4-6 This, and the clinical importance of the questions addressed, has heightened and renewed interest in perfusion scintigraphy.
Physical Advantages of 9mTc-Based Agents 99mTc-based perfusion agents promise to address many of the difficulties experienced with the current 20`T1 method of perfusion scintigraphy. Their physical characteristics present major differences in energy of emission (140-keV), physical half-life (6 hours), and mode of production (generator). The latter characteristic will increase radionuclide availability. The higher energy of emission will permit a larger administered dose with resultant high photon flux, allowing more refined collimation and providing high image quality with increased spatial resolution and reduced attenuation. These agents also offer the possibility of simultaneous function and perfusion assessment, currently requiring the application of alternate scintigraphic or other modalities. 7 Beyond this, the 99mTcbased perfusion agent hexakis 2-methoxyisobutyl isonitrile (Tc-MIBI) localizes intracellularly in association with mitochondria, and has been said to show little or no redistribution. This is the focus of the manuscript by De Coster and coworkers8 in this issue of Circulation. Consideration of this feature and other characteristics of 99mTc-labeled perfusion imaging agents under development will permit further evaluation of their impact on the noninvasive assessment of the cardiac patient.
The Identification of the Area At Ischemic Risk The main thesis of the article by De Coster et a18 is that in the absence of redistribution, Tc-MIBI and other isonitriles permit the accurate noninvasive delineation of myocardium subtended by the affected (occluded) vessel, the "area at risk" during coronary occlusion, even hours after radionuclide administration and under conditions of postreperfusion imaging. Some observations, however, in this study8 and others9,10 suggest that some redistribution does occur with time and possibly with reperfusion. Also, Tc-MIBI displays neither the rapid extraction nor high extraction fraction of 20`T, which may adversely effect imaging in association with dynamic, short-lived interventions. In this regard, 99mTc-labeled bornic acid derivatives such as 99mTc-teboroxime demonstrate more myocardial affinity with rapid extraction. 3, 9 Some previous studies9,10 have demonstrated slight but real redistribution of Tc-MIBI, while other studies'1 have confirmed the relative stability of radionuclide localization. The protocol of the current study was designed to reproduce the clinical setting of thrombolytic therapy. It differs from previous studies in the application of a long, 90-minute period of coronary occlusion, with comparison of occlusion and reperfusion scintigrams after a single injection made during occlusion. In this study,8 counts in the risk area maintained an unchanging relation to counts in the normal area. However, counts in myocardium distal to the occlusion were absolutely unchanged over the 3 hours of the study and 88% of segments counted showed 99mTc radioactivity variation of less than 10% on serial SPECT imaging. Although this could represent sampling effects, simple physical decay, not discussed by DeCoster et al, should result in a fall of radioactivity to 71% of the initial value for all sampled regions. One could say that the failure of this to occur reflects redistribution. However, counts in the normal region were also unchanged with time, presenting a puzzling observation that appears to defy basic laws of physics. Also, Figure 2 of Reference 8 plots serial radioactivity measurements in grouped matched biopsies obtained with occlusion and reperfusion. Mean values are indeed unchanging, but re-gional samples do decrease (possibly reflecting the expected decay), increase, or remain unchanged (possibly the result of redistribution). The grouped nature of the measured biopsy values also raises doubts about the slope of the line relating their absolute radioactivity, important to the manuscript's conclusions. Further, relative 99mTc radioactivity (Figure 3 of Reference 8) was generally higher postreperfusion than was relative microsphere radioactivity during occlusion, again indicating possible redistribution.
Practical Implications
All these issues aside, any variability of Tc-MIBI localization appears small, far less than that of 201T1, and did not affect image defect assessment, the final clinical endpoint for evaluation of the myocardial area at ischemic risk, in the study by De Coster et al. 8 These observations appear to be supported by prior work.13'4 Even when the quantitative analysis by De Coster et al appeared to demonstrate visual evidence of serial redistribution, the experienced reader would have difficulty identifying serial image differences and would certainly identify none of a clinically relevent nature.10 Although this issue may need further investigation and may in fact impact on clinical findings, let us now assume a lack of Tc-MIBI redistribution or, at least, of clinically relevent redistribution during the 3to 4-hour interval used. This "fixed" localization of a perfusion indicator is said by the authors to have significant advantages over other potential indicators for the identification and quantification of the myocardial "area at risk." Clinical Implications Obviously, accurate determination of "area at risk" could have great prognostic importance and is critically important in assessment of the effects of interventions. 20MT1 is currently the agent employed to assess myocardial perfusion. It has proven diagnostic accuracy and prognostic value, and strong evidence relates`01T1 distribution to viability.5,1516 201T1 distribution is the only parameter able to differentiate ischemic from infarcted myocardium and determine viability with a single injection in the setting of intervention or in the presence of ischemia at rest.17 Further, thallium defect size appears to correlate better with event rate and survival in the hours to days after acute infarction than do functional indicators and "hot spot" imaging agents.18 Apparently, 01T1 distribution best portrays both ischemia and infarction in this period, often reflecting the risk area and so best assessing prognosis. However, imaging with 9'Tc-based agents, and specifically with Tc-MIBI, makes more sense in certain situations.
The advantages of "'Tc-based perfusion imaging agents are related to their physical characteristics and to their potential effects on the logistics of the imaging protocol. Physical advantages will likely lead to use of these agents in association with dynamic and pharmacological interventions. The major benefits of these agents are related to the lack of redistri-bution and apply especially to the evaluation of perfusion in the acute ischemic setting, in the acute assessment of reperfusion postangioplasty, or after thrombolysis. Although 20`T1 perfusion scintigraphy has been successfully applied to the assessment of acute coronary reperfusion, it is quite impractical in the clinical setting. The authors correctly note that it is logistically ". . . impossible to obtain images prior to revascularization, since thrombolytic therapy is now routinely administered as early as possible after, or even prior, to hospital admission."8
The effectiveness of the 20'lM method as an acute care modality for the assessment of reperfusion is lessened by the interaction of its physical characteristics and the logistic needs of the acute care setting. Low availability of 201Tl can be overcome at times, but camera access and protected imaging time can be problematic, and constitute a major reason that the modality has not been more widely applied in this setting. Injection of 20'fl with immediate imaging could reveal the area at risk, but would delay the institution of therapy by at least 20-30 minutes, thus jeopardizing the possibility of reperfusion. Of course, early radionuclide administration with imaging delay and intervening reperfusion in the presence of myocardium at ischemic risk will alter the distribution of 201ol Theoretically, then, the image defect would represent the extent of remaining, irreversibly damaged myocardium, the component of thrombolytic failure, but this is only one component of the area at risk and a single element in the prognostic profile. Areas of uptake can be related to regional function and the identity of stunned myocardium. However, also within the perfused region is the unseen component of the risk area of viable myocardium, the component reperfused and salvaged, the component of thrombolytic success, the important reversible component of the risk area. Most important, the unseen area represents the territory still at potential risk, a fact that may aid guidance of subsequent therapy. Identification of area at risk, without interference with treatment delivery, appears to be a major advantage of Tc-MIBI and one that should certainly see the wide application of this 99"Tc-based agent in this acute setting.
The initial Tc-MIBI injection, given on admission or in the field prior to institution of reperfusion, can be imaged 2 hours after reperfusion, revealing the entire area at ischemic risk. Imaging after the second MIBI injection made a day or more later will reveal the component not salvaged. The difference will relate to the extent of myocardium salvaged and likely at continued ischemic risk.
Yet with advantages come some potential difficulties. Optimal and possibly necessary for Tc-MIBI imaging is SPECT acquisition. Here, planar imaging may miss defects obscured by overlying perfused regions or those in the distant background that would likely be attenuated if labeled with 201T1. Again, the absence of any significant redistribution provides no possibility for the assessment of continued ongoing ischemia. Furthermore, other 99mTc-based perfusion agents may present advantages for some applications beyond those of Tc-MIBI. However, the brief myocardial residence time of "9Tc-teboroxime appears to make that particular agent ill suited for use in the acute setting of reperfusion assessment.
As with any new modality or method, we should seek appropriate application of 9'Tc-based perfusion imaging while preserving early methods if some features make them more advantageous in specific settings. De Coster and coworkers8 present further data bearing on an aspect of Tc-MIBI kinetics that could have great clinical impact. If the findings prove durable and applicable to other isonitriles, 9'9Tc-based agents should make a broad and important contribution to reperfusion assessment. The findings of De Coster et al will have particular relevance to the application of Tc-MIBI in acute coronary care and the evaluation of reperfusion intervention and thrombolytic therapy.'9
